Benign missense variations in the cystic fibrosis gene. by Kobayashi, Keiko et al.
Am. J. Hum. Genet. 47:611-615, 1990
Benign Missense Variations in the Cystic Fibrosis Gene
Keiko Kobayashi,* Michael R. Knowles,t Richard C. Bouchert William E. O'Brien,*
and Arthur L. Beaudet*
*Howard Hughes Medical Institute and Institute for Molecular Genetics, Baylor College of Medicine, Houston; and tDepartment of Medicine,
University of North Carolina, Chapel Hill
Summary
The common mutation causing cystic fibrosis is a deletion of phenylalanine 508 (AF508), which occurs in
a putative nucleotide-binding fold of the gene product. We report two additional mutations, substitution of
cysteine for phenylalanine 508 (F508C) and substitution of valine for isoleucine 506 (1506V). Three com-
pound heterozygous persons, two AF508/F508C and one AF508/1506V, had normal clinical and epithelial
physiological studies indicating that the F508C and 1506V mutations are benign. This opportunity to
study the in vivo function of these mutations suggests that amino acid substitutions are more benign than
changes in the length of this portion of the putative nucleotide-binding fold. These mutations must be
taken into account when performing molecular diagnosis and carrier detection for cystic fibrosis.
Introduction
Cystic fibrosis (CF) is a well-known autosomal reces-
sive disorder affecting between one in 2,000 and one
in 3,000 individuals in the Caucasian population (Boat
et al. 1989). The disease affects epithelial cells in the
airways, pancreas, intestine, and sweat glands, leading
to chronic lung disease, pancreatic insufficiency, and
increased concentration of sodium and chloride in
sweat. The clinical, electrophysiological, and genetic
aspects of the disease were reviewed recently (Boat et
al. 1989). An intensive effort using genetic linkage in-
formation ultimately led to the cloning of the CF gene
prior to the identification of the gene product or its
function (Kerem et al. 1989; Riordan et al. 1989; Rom-
mens et al. 1989). The gene encodes what is believed
to be a transmembrane protein, which has been named
the cystic fibrosis transmembrane conductance regula-
tor (CFTR). The CFTR contains two nucleotide-
binding regions which show homology to numerous
transport proteins with the greatest homology to the
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P-glycoproteins that are encoded by the multiple drug-
resistance loci (Kerem et al. 1989; Riordan et al. 1989).
A three-base deletion resulting in the loss of
phenylalanine residue 508 (designated AF508) is the
mutation occurring on the majority of CF chromosomes
(Kerem et al. 1989; Riordan et al. 1989), being found
on 70O%-75%/o of North American CF chromosomes
(Kerem et al. 1989; Riordan et al. 1989; Lemna et al.
1990). During analysis of over 200 North American
CF families for the AF508 mutation, we identified three
parents who initially appeared to be homozygous for
the AF508 mutation (Lemna et al. 1990). We have now
determined that these three "index parents" are asymp-
tomatic compound heterozygotes carrying the AF508
mutation on one chromosome and a missense muta-
tion in the same region on the other chromosome.
Material and Methods
DNA Analysis
Genomic DNA was prepared and RFLPs were ana-
lyzed as described elsewhere (Lemna et al. 1990). For
XV-2c and KM-19, the 1 allele indicates the absence
of the polymorphic restriction-enzyme site and the 2
allele indicates the presence of the restriction-enzyme
site. Haplotypes ([XV-2c]-[KM-19]) are as follows: A
= 1-1, B = 1-2, C = 2-1, and D = 2-2. The poly-
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merase chain reactions (PCR) were performed in a final
volume of 50 gl containing 6.7 mM MgCl2, 67 mM
Tris HCl pH 8.8, 1.5 mM of each dNTP, 0.5 ,uM of
each PCR primer, 500 ng of genomic DNA, and one
unit of Taq polymerase (Perkin-Elmer/Cetus, Norwalk,
CT). The C16B and C16D primers (Kerem et al. 1989)
were modified to add restriction-enzyme sites as follows:
5'-GCTAGGTACCTCCTGGATTATGCCTGGCAC-3'
and 5'-GCTACTGCAGGTTGGCATGCTTTGATG-
ACG-3' (the underlined sequences are from the CF
gene). Reactions were heated to 940C for 5 min and
subjected to 30 cycles of denaturation at 940C for 1
min, annealing at 600C for 45 s, and DNA polymer-
ization at 720C for 2 min. After amplification, a por-
tion of the reaction mixture was analyzed by 3% agarose
and/or 10% acrylamide-gel electrophoresis to assess
the size of the amplified sequence and/or heteroduplex
formation.
For cloning and sequencing, the amplified product
was treated with phenol/chloroform, collected by etha-
nol precipitation, and digested with KpnI and PstI. The
specific fragment to be cloned was purified from low-
melting-point agarose following electrophoresis. DNA
fragments were directionally cloned into M13mp19 which
had been digested with KpnI and PstI. Single-stranded
DNA cloned into M13 was sequenced by the dideoxy
chain termination method (Biggin et al. 1983) using
Sequenase and universal primer (United States Biochem-
ical, Cleveland). A total of 49 M13 clones were sequenced
from the three index parents and from the three grand-
parents carrying the unusual allele. Hybridization with
allele-specific oligonucleotides was performed as de-
scribed elsewhere (Lemna et al. 1990), except for the
following variations. The allele-specific oligonucleotides
were as follows: normal = 5'-CACCAAAGATGATAT-
TTTC-3', AF508 = 5'-AACACCAATGATATTTT-
CTT-3', F508C = 5'-CACCACAGATGATATTTTC-3',
and 1506V = 5'-CAAAGATGACATTTTCTTT-3'.
Filters were washqd in 1 liter of 40 mM sodium phos-
phate buffer pH 7.2 containing 1% SDS for 5 min at
room temperature followed by a second wash in 500
ml for 15 min at 420C using prewarmed solution. Filters
were exposed using an intensifying screen for 2-3 h.
Physiological Studies
Sweat chloride was measured by pilocarpine ion-
tophoresis (Gibson and Cooke 1959). The cyclic
AMP-regulated sweat acinar Cl- secretion was as-
sessed by measuring the sweat rate in response to in-
tradermal injection of a mixture of isoproterenol, ami-
nophylline, and atropine (Sato and Sato 1984; 1988).
Samples were collected at timed intervals under oil, and
volume was measured in constant-bore calibration
pipettes. CF patients (n = 14) did not sweat in response
to this maneuver. The sweat-ductal potential difference
(PD) was determined by measurement of the sweat-
droplet PD under oil using a glass electrode filled with
saturated KCl-agar and referenced to a subcutaneous
electrode (Quinton and Bijman 1983; Bijman and Quin-
ton 1984). The voltage for each subject is the average
of 5-9 glands. The sweat-duct PD of 11 CF patients
ranged from -46.3 to -80 mV. The nasal bioelectric
parameters were measured as described elsewhere
(Knowles et al. 1981, 1983a, 1983b). The mean nasal
transepithelial PD and response to superfusion of drugs
and ionic solutions were assessed via a Ringer-perfused
exploring bridge referenced to a subcutaneous electrode.
Inhibition with 10-4 M amiloride was calculated as
percentage from baseline. The Cl- -diffusion PD (an in-
dex of Cl- permeability) is the voltage change recorded
during superfusion of a Cl--free solution with 10-5
M isoproterenol in the presence of amiloride; a nega-
tive change indicates hyperpolarization.
Results
Family studies using allele-specific oligonucleotides
to detect the normal and AF508 sequences revealed un-
usual results in three unrelated families (Lemna et al.
1990). Each family had an index parent whose DNA
hybridized only to the AF508 oligonucleotide, which
would imply that these apparently healthy parents were
homozygous for the AF508 allele and were affected with
CE In addition, each index parent had one parent who
was unexpected in that theirDNA hybridized only with
the normal oligonucleotide. Analysis of the amplified
DNA from each index parent on a 10% acrylamide gel
(Rommens et al. 1990) revealed heteroduplex forma-
tion, indicating that these individuals were heterozy-
gous in some way and must carry a distinctive allele,
which yielded amplified DNA that did not hybridize
with either the normal or the AF508 oligonucleotides.
The major portion of exon 10 was amplified from
genomic DNA from each index parent and the respec-
tive grandparent suspected of carrying the unusual chro-
mosome. The C16B and C16D oligonucleotides (Kerem
et al. 1989) were modified to add restriction-enzyme
sites, and the products were cloned into M13 phage for
DNA sequencing. As shown in figure 1, one mutant
sequence included TGT at residue 508, causing a
phenylalanine-to-cysteine substitution (F508C). A sec-
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Figure I DNA sequence for two missense mutations. M13
clones from various individuals in the three families studies were se-
quenced, and examples of the normal and mutant sequences are
shown. NL = normal; AF508, F508C, and I506V are mutant se-
quences described in the text. The nucleotide and amino acid se-
quence for positions 505-509 are depicted below.
ond mutant sequence included GTC at position 506,
causing an isoleucine-to-valine substitution (1506V).
The FS08C mutation was found in two Caucasian fam-
ilies on a chromosome carrying the C haplotype for
the XV-2c and KM-19 markers (Lemna et al. 1990).
The other family was Hispanic, and the I506V muta-
tion was present on a chromosome with the B haplo-
type. More extensive haplotypes for the mutant chro-
mosomes were as follows: 1121122 for both chromosomes
with the F508C mutation and 2112212 for the I506V
chromosome. Haplotype markers in order are MetD/
BanI, MetD/TaqI, XV-2c/TaqI, KM-19/PstI, E2.6/
Mspl, J44/XbaI, and J3.11/MspI (Kerem et al. 1989).
In order to confirm these mutations and study their
inheritance within the three families, allele-specific oli-
gonucleotides were prepared for each of the mutant se-
quences. Genomic DNA was amplified using the C16B
and C16D primers, and hybridization was performed
using four different allele-specific oligonucleotides (nor-
mal, AFS08, F508C, and I506V) as shown in figure 2.
For all three families (only two are shown in fig. 2),
the child affected with CF was homozygous for the
AFS08 mutation. The index parent was a compound
heterozygote carrying the AFS08 allele and either the
FS08C or the IS06V allele. In all cases, the index par-
ent had a parent who was heterozygous for the AFS08
allele and another parent who was heterozygous for
either the FS08C or the IS06V allele. In one family
depicted in figure 2, the compound heterozygous mother
had two sisters with the same genotype. Using these
allele-specific oligonucleotides, we rescreened approx-
imately 440 normal and CF chromosomes and did not
identify any other families carrying these alleles. This
gave a frequency of approximately 2/440 apparently
normal chromosomes carrying the FS08C mutation and
1/440 apparently normal chromosomes carrying the









Figure 2 Family analysis with allele-specific oligonucleotides. Genomic DNA was amplified, applied to a slot-blot apparatus, and
hybridized to each oligonucleotide. Left, Family W; right, family G. Solid gene symbols indicate individuals affected with CF. Solid half-





Physiological Studies on Three Compound Heterozygous Parents
FORCED NASAL BIOELECTRIC PARAMETERS
EXPIRATORY SWEAT RATE IN
VOLUME IN RESPONSE TO SWEAT- Amiloride
1 S (% of SWEAT CL_ ISOPROrERENOL DUCT PD Mean PD Inhibition Cl -Diffusion
FAMILYa AGE SEX predicted) (meq/liter) (nl/min/gland) (mV) (mV) (%) PD (mV)
W .38 F 110 32,33 .8 -23.0 -28.3 49.5 -41.5
R .39 M 105 34,37 1.5 -23.6 -20.6 45.9 -47.0
G .36 M 88 19,22 1.2 -18.1 -15.1 56.9 -24.0
Normal range 80-120 <60 .2-3.0 -10 to -45 -10 to -40 <70 -15 to -60
NOTE.-The sweat Cl- and forced expiratory volume in 1 s are standard clinical parameters. Other parameters are described in Material
and Methods.
a The genotype for index parents from familiesW and R is AF508/F508C and that for the index parent from family G is AF508/1506V.
served on CF chromosomes, although an allele-specific
oligonucleotide designed to hybridize to the I506V and
the AF508 mutations on the same chromosome was
not tested.
To determine whether these missense mutations were
benign or caused disease, clinical evaluation and studies
designed to detect expression of CF-specific respiratory
or sweat-gland epithelial abnormalities were performed.
The parent from family W had intermittent rhinitis,
but no sinusitis or other pulmonary symptoms. The
parent from family R reported episodes of "pneumo-
nia" in 1972 and 1977, but had no chronic pulmonary
complaints. The parent from family G smokes ciga-
rettes (one pack per day for 20 years) and had an inter-
mittent cough sometimes productive of mucopurulent
secretions. Each of the three individuals had a normal
physical examination, chest radiograph, and serum tryp-
sinogen and vitamin E. Spirometry was normal in all
three parents except for mild airflow obstruction at lower
lung volumes in one parent (table 1, family G) compat-
ible with his smoking history. Each of the three indi-
viduals exhibited normal sweat-gland and respiratory
epithelial functional characteristics (table 1), including
basal transepithelial bioelectric properties, response to
cyclic AMP-dependent Cl- secretagogues, and Cl-
permselectivity. Thus, these parents exhibited no evi-
dence of the clinical disease or epithelial dysfunction
which is seen with even "mild" CF (Stern et al. 1977;
Evensen 1981; Knowles et al. 1989).
Discussion
Since the phenotype for the AF508 allele is known
to be severe CF, the clinical and physiological data for
the three compound heterozygote parents indicate that
the F508C and I506V alleles must be benign. It is pos-
sible that these missense alleles could cause CF-like
phenotypes in other genotypic combinations, although
this seems unlikely. Since the entire gene was not se-
quenced, there is also a small possibility that the alleles
carrying the F508C or I506V mutations could contain
second mutations which balance a potential deleteri-
ous effect; this would leave open the possibility that
the F508C or I506V mutations alone might be patho-
logical. These F508C and 1506V mutations might be
found in the future on CF chromosomes carrying other
deleterious mutations. This would be similar to the del-
eterious alleles at the al-antitrypsin locus which are
found in various combinations with other benign amino
acid substitutions within the gene (Cox 1989). This
would likely occur by sequential independent mutation,
although recombination and gene conversion are pos-
sible. At the present time, if the F508C or 1506V alleles
are found on CF chromosomes, it should be presumed
that there is a deleterious mutation elsewhere in the
gene until proven otherwise. The existence of these al-
leles further emphasizes how uncommon genetic vari-
ation can cause diagnostic pitfalls in molecular diag-
nosis. Variation in the DNA sequence at the site of
allele-specific oligonucleotides or at the site of primers
used for amplification (Fujimura et al. 1990) can lead
to diagnostic errors.
The molecular, clinical, and physiological data in
these three compound heterozygous parents indicate
that the amino acid sequence in the F508 region of the
CFTR need not be rigidly conserved in order to main-
tain adequate gene function. In particular, the F508C
allele represents a nonconservative substitution, but
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there is no detectable phenotypic effect. This informa-
tion in combination with the knowledge that the AF508
(Kerem et al. 1989) causes the clinical syndrome of CF
suggests that the length of this region of the CFTR pro-
tein is more important than the exact amino acid
residues which are present. These missense mutations
occur in a slightly less conserved portion of the
nucleotide-binding fold between two more highly con-
served motifs (Higgins et al. 1988). This type of in vivo
mutational analysis is extremely valuable in assessing
the structure-function relationships of the CF gene
product.
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